A detailed history of Stephens Consulting, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Stephens Consulting, LLC holds 1,738 shares of ABBV stock, worth $286,752. This represents 0.09% of its overall portfolio holdings.

Number of Shares
1,738
Previous 1,750 0.69%
Holding current value
$286,752
Previous $300 Million 14.31%
% of portfolio
0.09%
Previous 0.09%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

SELL
$163.84 - $199.33 $1,966 - $2,391
-12 Reduced 0.69%
1,738 $343 Million
Q2 2024

Jul 29, 2024

BUY
$154.79 - $180.76 $3,714 - $4,338
24 Added 1.39%
1,750 $300 Million
Q1 2024

Apr 17, 2024

SELL
$159.82 - $182.1 $2,876 - $3,277
-18 Reduced 1.03%
1,726 $314 Million
Q4 2023

Feb 01, 2024

SELL
$137.6 - $154.97 $4,403 - $4,959
-32 Reduced 1.8%
1,744 $270 Million
Q3 2023

Oct 25, 2023

SELL
$133.59 - $154.65 $6,545 - $7,577
-49 Reduced 2.68%
1,776 $265 Million
Q2 2023

Jul 20, 2023

SELL
$132.51 - $164.9 $2,385 - $2,968
-18 Reduced 0.98%
1,825 $246 Million
Q1 2023

Apr 19, 2023

SELL
$144.61 - $166.54 $18,799 - $21,650
-130 Reduced 6.59%
1,843 $294 Million
Q4 2022

Jan 19, 2023

SELL
$138.31 - $165.87 $16,873 - $20,236
-122 Reduced 5.82%
1,973 $319 Million
Q3 2022

Jan 19, 2023

SELL
$134.21 - $153.93 $16,910 - $19,395
-126 Reduced 5.67%
2,095 $281 Million
Q2 2022

Jan 19, 2023

SELL
$137.62 - $174.96 $3,302 - $4,199
-24 Reduced 1.07%
2,221 $340 Million
Q1 2022

Jan 19, 2023

SELL
$131.98 - $163.75 $35,898 - $44,540
-272 Reduced 10.81%
2,245 $364 Million
Q4 2021

Jan 19, 2023

BUY
$107.43 - $135.93 $270,401 - $342,135
2,517 New
2,517 $341 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $292B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Stephens Consulting, LLC Portfolio

Follow Stephens Consulting, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stephens Consulting, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Stephens Consulting, LLC with notifications on news.